Towards Optimal Treatment for High Risk Prostate Cancer
ConditionHigh Risk Prostate Carcinoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18+
SponsorHaaglanden Medical Centre
About this trial
The goal of this clinical trial is to combine several optimized treatments of high risk prostate cancer. The main question to answer is: is it safe to combine these optimized treatments.
* patients will be irradiated on the prostate and (elective) lymph nodes more concentrated but with fewer hospital visits (hypofractionation) * the tumor will get a higher dose * androgen deprivation therapy will be reduced as much al possible preventing side effects
Researchers will compare oncological outcome and toxicity.
Eligibility criteria
Qualifiers
T3 based on digital rectal examination AND/OR
Grade >= 4 AND/OR
PSA >=20 ug/L
Indication for elective lymph node irradiation (based on current clinical guidelines) OR N1 on imaging (with a maximum of 4 suspect lymph nodes)
Disqualifiers
Prior pelvic radiotherapy
TransUrethral Resection of the Prostate (TURP) < 3 months ago
Prostatectomy or other primary treatment for prostate cancer (e.g. HIFU, cryotherapy, etc)
contraindications to MRI
Trial design
Treatments tested in this trial
- HYPOPRIME treatment
Treatment groups
207 Participants
are divided into 1 treatment groupSponsors and collaborators
Haaglanden Medical Centre
Lead sponsor
Tata Memorial Centre
Collaborator
Source ClinicalTrials.gov